scholarly journals Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis

1998 ◽  
Vol 26 (1) ◽  
pp. 56-60 ◽  
Author(s):  
Miller ◽  
McBride ◽  
Manchee ◽  
Moore ◽  
Baillie
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Protective Efficacy ◽  
Recombinant Protective Antigen

scholarly journals A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection

2002 ◽  
Vol 70 (3) ◽  
pp. 1653-1656 ◽  
Author(s):  
Helen C. Flick-Smith ◽  
Nicola J. Walker ◽  
Paula Gibson ◽  
Helen Bullifent ◽  
Sarah Hayward ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Fusion Proteins ◽  
Protective Antigen ◽  
Protective Efficacy ◽  
Terminal Domain ◽  
Carboxy Terminal Domain ◽  
Anthrax Infection ◽  
Carboxy Terminal ◽  
Domain 4

ABSTRACT The immunogenicity and protective efficacy of overlapping regions of the protective antigen (PA) polypeptide, cloned and expressed as glutathione S-transferase fusion proteins, have been assessed. Results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of PA.

scholarly journals Attenuated Nontoxinogenic and Nonencapsulated Recombinant Bacillus anthracis Spore Vaccines Protect against Anthrax

2000 ◽  
Vol 68 (8) ◽  
pp. 4549-4558 ◽  
Author(s):  
S. Cohen ◽  
I. Mendelson ◽  
Z. Altboum ◽  
D. Kobiler ◽  
E. Elhanany ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Protective Immunity ◽  
Protective Antigen ◽  
Cell Vaccine ◽  
Lethal Challenge ◽  
Electrospray Mass Spectroscopy ◽  
Immunological Tests ◽  
Anthrax Spores ◽  
Biochemical Analyses ◽  
Recombinant Protective Antigen

ABSTRACT Several highly attenuated spore-forming nontoxinogenic and nonencapsulated Bacillus anthracis vaccines differing in levels of expression of recombinant protective antigen (rPA) were constructed. Biochemical analyses (including electrospray mass spectroscopy and N terminus amino acid sequencing) as well as biological and immunological tests demonstrated that the rPA retains the characteristics of native PA. A single immunization of guinea pigs with 5 × 107 spores of one of these recombinant strains, MASC-10, expressing high levels of rPA (≥100 μg/ml) from a constitutive heterologous promoter induced high titers of neutralizing anti-PA antibodies. This immune response was long lasting (at least 12 months) and provided protection against a lethal challenge of virulent (Vollum) anthrax spores. The recombinant B. anthracis spore vaccine appears to be more efficacious than the vegetative cell vaccine. Furthermore, while results clearly suggest a direct correlation between the level of expression of PA and the potency of the vaccine, they also suggest that some B. anthracisspore-associated antigen(s) may contribute in a significant manner to protective immunity.

scholarly journals Correlation between Lethal Toxin-Neutralizing Antibody Titers and Protection from Intranasal Challenge with Bacillus anthracis Ames Strain Spores in Mice after Transcutaneous Immunization with Recombinant Anthrax Protective Antigen

2006 ◽  
Vol 74 (1) ◽  
pp. 794-797 ◽  
Author(s):  
Kristina K. Peachman ◽  
Mangala Rao ◽  
Carl R. Alving ◽  
Robert Burge ◽  
Stephen H. Leppla ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Neutralizing Antibody ◽  
Lethal Toxin ◽  
Vaccine Strategy ◽  
Transcutaneous Immunization ◽  
Antibody Titers ◽  
Anthrax Protective Antigen ◽  
Ames Strain ◽  
Recombinant Protective Antigen

ABSTRACT Transcutaneous immunization of mice with recombinant protective antigen (rPA) of Bacillus anthracis resulted in significantly higher lethal toxin-neutralizing antibody titers than did intramuscular injection of alum-adsorbed rPA. Immunized mice were partially protected against intranasal challenge with 235,000 (10 50% lethal doses) Ames strain B. anthracis spores. A highly significant correlation was observed between toxin-neutralizing antibody titer and survival after challenge. Future experiments with rabbits and nonhuman primates should confirm the significance of protection by this vaccine strategy.

scholarly journals Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen

2020 ◽  
pp. 1-6
Author(s):  
Ekaterina M. Ryabchevskaya ◽  
Ekaterina A. Evtushenko ◽  
Dmitry L. Granovskiy ◽  
Peter A. Ivanov ◽  
Joseph G. Atabekov ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Recombinant Protective Antigen

scholarly journals Reference materials of catalytic activity as a means of ensuring the metrological traceability of measurement results. KATAL

2019 ◽  
Vol 14 (1-2) ◽  
pp. 25-32
Author(s):  
E. V. Kulyabina ◽  
O. N. Melkova ◽  
E. A. Guskova ◽  
T. V. Grebennikova
Keyword(s):  
Catalytic Activity ◽  
Bacillus Anthracis ◽  
Reference Materials ◽  
Mass Concentration ◽  
Ebola Virus ◽  
Protective Antigen ◽  
Metrological Traceability ◽  
Measurement Results ◽  
Traceability Of Measurement Results ◽  
Recombinant Protective Antigen

Introduction. The article considers the problems of metrological support of catalytic activity measurements. The paper gives certain characteristics of the State Primary Special Measurement Standard for the unit of catalytic activity – KATAL and examines the role of reference materials (RMs) in ensuring the metrological traceability of measurement results.Materials and methods. A method for measuring the concentration of the recombinant protective antigen of Bacillus anthracis and the recombinant GP-protein of the Ebola virus, which means in using «sandwich» enzyme-linked immunosorbent assay, was certified by FGUP «VNIIMS» as a measurement procedure. The following RMs tested by FGUP «VNIIMS» can be used for the development and production of appropriate control samples when performing measurements for comparisons: the RM for the mass concentration of the recombinant protective antigen of Bacillus anthracis in phosphate-saline solution, the RM for the mass concentration of the recombinant GP-protein of the Ebola virus, and the RM for the mass concentration of recombinant Clostridium Difficile toxin.Results. The paper presents the main reactions of the method for measuring the catalytic activity of catalysts for heterogeneous processes, which are also used to carry out exhaust gas cleaning processes.Discussion and conclusions. Thus, conditions have been created for building hierarchies of calibrations of in-demand objects established on the basis of the List of Critical Technologies of the Russian Federation, state programs for the development of industrial sectors.

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine☆

Vaccine ◽  
2006 ◽  
Vol 24 (14) ◽  
pp. 2530-2536 ◽  
Author(s):  
S.F. Little ◽  
B.E. Ivins ◽  
W.M. Webster ◽  
P.F. Fellows ◽  
M.L.M. Pitt ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Antigen Vaccine ◽  
Duration Of Protection ◽  
Recombinant Protective Antigen

scholarly journals Immunogenicity and Protective Efficacy of a Non-Living Anthrax Vaccine versus a Live Spore Vaccine with Simultaneous Penicillin-G Treatment in Cattle

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 595
Author(s):  
Solomon Jauro ◽  
Okechukwu C. Ndumnego ◽  
Charlotte Ellis ◽  
Angela Buys ◽  
Wolfgang Beyer ◽  
...  
Keyword(s):  
Protective Antigen ◽  
Protective Efficacy ◽  
Lethal Dose ◽  
Passive Immunization ◽  
Penicillin G ◽  
Passive Immunisation ◽  
Protective Capacity ◽  
Anthrax Vaccine ◽  
Recombinant Protective Antigen

Sterne live spore vaccine (SLSV) is the current veterinary anthrax vaccine of choice. Unlike the non-living anthrax vaccine (NLAV) prototype, SLSV is incompatible with concurrent antibiotics use in an anthrax outbreak scenario. The NLAV candidates used in this study include a crude recombinant protective antigen (CrPA) and a purified recombinant protective antigen (PrPA) complemented by formalin-inactivated spores and Emulsigen-D®/Alhydrogel® adjuvants. Cattle were vaccinated twice (week 0 and 3) with NLAVs plus penicillin-G (Pen-G) treatment and compared to cattle vaccinated twice with SLSV alone and with Pen-G treatment. The immunogenicity was assessed using ELISA against rPA and FIS, toxin neutralisation assay (TNA) and opsonophagocytic assay. The protection was evaluated using an in vivo passive immunisation mouse model. The anti-rPA IgG titres for NLAVs plus Pen-G and SLSV without Pen-G treatment showed a significant increase, whereas the titres for SLSV plus Pen-G were insignificant compared to pre-vaccination values. A similar trend was measured for IgM, IgG1, and IgG2 and TNA titres (NT50) showed similar trends to anti-rPA titres across all vaccine groups. The anti-FIS IgG and IgM titres increased significantly for all vaccination groups at week 3 and 5 when compared to week 0. The spore opsonising capacity increased significantly in the NLAV vaccinated groups including Pen-G treatment and the SLSV without Pen-G but much less in the SLSV group with Pen-G treatment. Passive immunization of A/J mice challenged with a lethal dose of 34F2 spores indicated significant protective capacity of antibodies raised in the SLSV and the PrPA + FIS + adjuvants vaccinated and Pen-G treated groups but not for the NLAV with the CrPA + FIS + adjuvants and the SLSV vaccinated and Pen-G treated group. Our findings indicate that the PrPA + FIS + Emulsigen-D®/Alhydrogel® vaccine candidate may provide the same level of antibody responses and protective capacity as the SLSV. Advantageously, it can be used concurrently with Penicillin-G in an outbreak situation and as prophylactic treatment in feedlots and valuable breeding stocks.

Sign in / Sign up

Export Citation Format

Share Document